Development of Asymmetric Facial Depigmentation in a Patient Treated with Dasatinib with New-Onset Hypovitaminosis D: Case Report and Review of the Literature

• Главные авторы: Kirsten C. Webb (Автор), Magdalena Harasimowicz (Автор), Monica Janeczek (Автор), Jodi Speiser (Автор), James Swan (Автор), Rebecca Tung (Автор)
• Формат: ‌
• Опубликовано: Hindawi Limited, 2017-01-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Dasatinib is a second-generation tyrosine kinase inhibitor (TKI) used to treat imatinib-resistant chronic myelogenous leukemia (CML), as well as other Philadelphia chromosome-positive lymphoproliferative disorders. While the most commonly reported cutaneous side effects with this therapy include a m...